Moon Surgicala French-American pioneer in the field of surgical innovation, announced the admission of Scopilot by the US Food and Drug Administration (FDA). Enabled by NVIDIA Holoscana real-time sensor platform that is designed for the development and use of applications based on artificial intelligence in the operating room and is carried out locally under Moon Surgical’s Maestro system. Scopilot is the first AI application that runs intraoperatively on every commercially available surgical robot platform with Holoscan.
Scopilot is a AI-based function of the Maestro system, which guarantees a stable and ideal view during the operation and is intended to improve control, security and efficiency in the operating room. Scopilot enables the laparoscope connected to a Maestro system seamlessly to follow a desired instrument tip and is easy to use. Surgeons control the positioning of the laparoscope without loosening from the instruments in their hands and can thus maintain the surgical flow and concentration.
“Scopilot enables surgeons to control three instruments with only two hands and at the same time offers a stable, constant optimal and safe field of vision that is of crucial importance during the operation,” said Anne Osdoit, CEO from Moon Surgical and partner at Medtech-Accelerators MD Start of Sofinnova Partners. “The tax functions that Maestro scopilot offers will increase efficiency in the operating room by making surgeons autonomous and at the same time improving visualization of the procedure.”
Moon Surgical’s commercial Maestro system, which was approved by the FDA in June 2024, has already been used for the treatment of more than 1,100 patients in the United States and Europe and includes general, bariatric, gynecological and urological operations. With its unique and comprehensive environmental acquisition, coupled with accelerated Nvidia computing and AI, Maestro generates an unprecedented surgical data set with multimodal recording and kinematics and thus drives the development of next generation physical-AI functions that the surgical care as well as in the entire perioperative workflow improve.
“The software -defined platform from Moon Surgical has changed the industry and led to a continuous current of groundbreaking breakthroughs in the surgical robotics industry,” said Kimberly Powell, Vice President of Healthcare at Nvidia. “With Scopilot, Moon Surgical has accomplished the incredible feat, to integrate the first AI-controlled surgical movement solution approved by the FDA into a robotics platform and operate with Holoscan.”
Informations in Moon Surgical
Moon Surgical, based in Paris and San Francisco, builds the operation of the future, which is digitized, efficient and sustainable. The combined performance of the transformative Maestro system and the intelligent Maestro Insights enables health teams to make safe decisions and to ensure better surgical care for their patients. The company Moon Surgical, founded in 2020, is proud to remain flexible, to put innovations in the foreground and to promote inclusion, creativity and cooperation in its multicultural team.
Moon Surgical. Inspire and renew the art of surgery.
Visit us under www.moonsurgical.com Or follow us LinkedIn.
Photo – https://mma.prnewswire.com/media/2644434/DSC04634.jpg
Logo – https://mma.prnewswire.com/media/2255002/5222384/Moon_Surgical_Noir_Logo.jpg
